The comprehensive review by Kyriazoglou and colleagues [101] summarizes the results of the clinical trials using these drugs in HER2 BC through 2020, and the authors conclude that checkpoint inhibitors are tolerable and safe, and, overall, show some positive results, but the clinical benefit is still debatable. This evidence concerns the gene ERBB2 and breast cancer.